VIDEO: Antibody-drug conjugates show promise for EGFR-mutated lung cancer

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

There are many assets with many different mechanism of actions going into the EGFR development pipeline, which is quite exciting. The most advanced, I will say, have to be antibody drug conjugates. At least two of them. One is a HER3 ADC. The other is a TROP2 ADC, has show excellent preliminary data. Potentially can be approved for EGFR refractory, TKI refractory patient population. And there are many other ADC, with various different targets, different linker, different payload, entering the space. We do stop developing novel targeted therapy, novel TKI. We have even higher potency. '

We have a penetrating TTI, fourth generation entering the space as well, trying to improve upon osimertinib and losartan. We also have newer generation of immunotherapy, as we know, that the PD-1, PD-L1 immune check blockade, that doesn't work for EGFR mutation cancers. But the novel approach, like T-cell engager, CAR approach or TIL, are entering the space. And of course, all the above can be mix and matched as a novel combination. So the field is still quite exciting, and very competitive for drug development for EGFR lung cancer.